Divergent Expression of IL-1 Receptor Antagonists in CD34 +Fibrocytes and Orbital Fibroblasts in Thyroid-associated Ophthalmopathy: Contribution of Fibrocytes to Orbital Inflammation

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages 2783-2790

  Li, Bin ^a   Smith, Terry J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; PROSTAGLANDIN SYNTHASE; RNA POLYMERASE II;

ARTICLE; CELL SELECTION; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC ANALYSIS; GENETIC STABILITY; HUMAN; HUMAN CELL; INTERLEUKIN 1 RECEPTOR ANTAGONIST GENE; INTERLEUKIN 1ALPHA GENE; INTERLEUKIN 1BETA GENE; MOLECULAR DYNAMICS; ORBIT INFLAMMATION; ORBITAL FIBROBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN SYNTHASE GENE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STEADY STATE; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIGENS, CD34; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; CYCLOOXYGENASE 2; DISEASE SUSCEPTIBILITY; FIBROBLASTS; GENE EXPRESSION REGULATION; GRAVES OPHTHALMOPATHY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; LEUKOCYTES; ORBIT; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; RNA STABILITY; RNA, MESSENGER;

EID: 84879992626     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1245     Document Type: Article

References (38)

1. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726-738.
2. Smith TJ. Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest. 2010;33:414-421.
3. Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87:385-392.
4. Smith TJ, Sempowski GD, Wang HS, Del Vecchio PJ, Lippe SD, Phipps RP. Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. J Clin Endocrinol Metab. 1995;80:2620-2625.
5. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998;273:29615-29625. (Pubitemid 28509970)
6. Wang HS, Cao HJ, Winn VD, et al. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J Biol Chem. 1996;271:22718-22728. (Pubitemid 26304717)
7. Cao HJ, Smith TJ. Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. Am J Physiol. 1999;277:C1075-C1085. (Pubitemid 30045964)
8. Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol. 1998;274:C707-C714.
9. Fernando R, Atkins S, Raychaudhuri N, et al. Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci USA. 2012;109:7427-7432.
10. Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95:430-438.
11. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6:232-241.
12. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' opthalmopathy patients. Clin Endocrinol. 2003;58:280-287. (Pubitemid 36308115)
13. Sciaky D, Brazer W, Center DM, Cruikshank WW, Smith TJ. Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol. 2000;164:3806-3814. (Pubitemid 30169838)
14. Han R, Smith TJ. Induction by IL-1β of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and interferon γ. J Immunol. 2005;174:3072-3079. (Pubitemid 40279729)
15. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest. 1991;88:1445-1451.
16. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol. 1993;54:167-227. (Pubitemid 23289253)
17. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27-55. (Pubitemid 28183358)
18. Malyak M, Smith MF Jr, Abel AA, Hance KR, Arend WP. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol. 1998;161:2004-2010. (Pubitemid 28387626)
19. Mühlberg T, Joba W, Spitzweg C, Schworm HD, Heberling HJ, Heufelder AE. Interleukin-1 receptor antagonist ribonucleic acid and protein expression by cultured Graves' and normal orbital fibroblasts is differentially modulated by dexamethasone and irradiation. J Clin Endocrinol Metab. 2000;85:734-742. (Pubitemid 32273662)
20. Bartalena L, Manetti L, Tanda ML, et al. Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clin Endocrinol. 2000;52:647-651. (Pubitemid 30337092)
21. Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, opthalmopathy and cigarette smoking. Eur J Endocrinol. 2000;2:197-202. (Pubitemid 30622353)
22. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997;99:2930-2940. (Pubitemid 27278670)
23. Smith TJ. Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones. J Clin Invest. 1984;74:2157-2163. (Pubitemid 15197361)
24. Smith TJ, Padovani-Claudio DA, Lu Y, et al. Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab. 2011;96:3827-3837.
25. Gillespie EF, Konstantinos PI, Fernando R, et al. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab. 2012;97:E740-E746.
26. Tsui S, Fernando R, Chen B, Smith TJ. Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease. J Biol Chem. 2011;286:24487-24499.
27. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-β and peroxisome proliferator-activated receptor gamma. J Biol Chem. 2007;282:22910-22920. (Pubitemid 47267358)
28. Bittencourt D, Auboeuf D. Analysis of co-transcriptional RNA processing by RNA-ChIP assay. Methods Mol Biol. 2012;809:563-577.
29. Opp MR, Krueger JM. Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol. 1991;260:R453-R457.
30. Romero R, Sepulveda W, Mazor M, et al. The natural interleukin-1 receptor antagonist in term and preterm parturition. Am J Obstet Gynecol. 1992;167:863-872.
31. Huang HY, Wen Y, Kruessel JS, Raga F, Soong YK, Polan ML. Interleukin (IL)-1β regulation of IL-1β and IL-1 receptor antagonist expression in cultured human endometrial stromal cells. J Clin Endocrinol Metab. 2001;86:1387-1393. (Pubitemid 32323032)
32. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323-340.
33. Cao HJ, Han R, Smith TJ. Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am J Physiol Cell Physiol. 2003;284:C1429-C1437. (Pubitemid 36583384)
34. Butcher C, Steinkasserer A, Tejura S, Lennard AC. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol. 1994;153:701-711. (Pubitemid 24206299)
35. Evans I, Dower SK, Francis SE, Crossman DC, Wilson HL. Action of intracellular IL-1Ra (Type 1) is independent of the IL-1 intracellular signalling pathway. Cytokine. 2006;33:274-280.
36. Levine SJ, Wu T, Shelhamer JH. Extracellular release of the type I intracellular IL-1 receptor antagonist from human airway epithelial cells: differential effects of IL-4, IL-13, IFN-gamma, and corticosteroids. J Immunol. 1997;158:5949-5957. (Pubitemid 127484004)
37. Watson JM, Lofquist AK, Rinehart CA, et al. The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1 β. J Immunol. 1995;155:4467-4475.
38. Tsai LJ, Lan JL, Lin CY, Hsiao SH, Tsai LM, Tsai JJ. The different expression patterns of interleukin-1 receptor antagonist in systemic lupus erythematosus. Tissue Antigens. 2006;68:493-501.